• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Brand Institute Partners on Brand Name Development for FDA-Approved Treatment for Pulmonary Arterial Hypertension


Brand Institute is proud to announce its work with CMP Pharma in developing the brand name TADLIQ®, for tadalafil oral suspension, which was approved by the FDA on June 17, 2022.

TADLIQ is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and also holds the distinction of being the first and only FDA-approved oral suspension of tadalafil.

PAH is a progressive disorder characterized by abnormally high blood pressure (hypertension) in the pulmonary artery, the blood vessel that carries blood from the heart to the lungs. PAH is one form of a broader condition known as pulmonary hypertension (PH).

Recent Videos
Related Content